---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-061119"
form_type: "8-K"
ticker: "XENE"
cik: "0001582313"
company_name: "Xenon Pharmaceuticals Inc."
filed_at: "2023-11-08T23:59:59+00:00"
generated_at: "2026-06-08T09:30:01.153995+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Xenon Q3 net loss $48.5M; XEN1101 MDD trial topline due late Nov–mid Dec

## Summary
- Net loss $48.5M in Q3 2023 vs $37.2M in Q3 2022; cash $639.1M, funding operations into 2026.
- XEN1101 Phase 2 X-NOVA MDD trial topline results expected late November to mid-December 2023.
- Phase 3 epilepsy trials X-TOLE2, X-TOLE3, X-ACKT ongoing; X-TOLE2 enrollment to complete H2 2024.
- Neurocrine to report NBI-921352 adult focal study data in November 2023.
- R&D expenses increased to $42.9M from $29.4M, driven by XEN1101 clinical advancement.

## SEC filing metadata
- accession: 0000950170-23-061119
- form_type: 8-K
- ticker: XENE
- cik: 0001582313
- company_name: Xenon Pharmaceuticals Inc.
- filed_at: 2023-11-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1582313/000095017023061119/0000950170-23-061119-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1582313/000095017023061119/xene-20231108.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-061119
- JSON: https://secwatch.observer/filing/0000950170-23-061119.json
- Plain text: https://secwatch.observer/filing/0000950170-23-061119.txt

## Key facts
- Earnings Releases
  Xenon Pharmaceuticals Inc. reported the third quarter ended September 30, 2023 results: revenue No revenue was recognized.
  - Period: the third quarter ended September 30, 2023
  - Revenue: No revenue was recognized
  - Result: reported results
  source text: Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today reported financial results for the third quarter ended September 30, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1582313/000095017023061119/0000950170-23-061119-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.